Researchers tested the use of wearables to remotely monitor patients with depression, MS and epilepsy
“Over six years, RADAR-CNS has been finding answers to questions about the viability and usefulness of smartphones and wearable tech for managing illness, and the steps that need to be taken to integrate these into clinical practice.” Professor Matthew Hotopf, vice-dean of research, King’s College London
A technology platform has been developed that allows the real-time collection of health data from numerous sources, making it possible to remotely monitor multiple conditions.
The platform is the result of a six-year project led by King’s College London and Janssen Pharmaceutica NV and involving 22 organisations across Europe and the United States. The Remote Assessment of Disease and Relapse – Central Nervous System Consortium (RADAR-CNS) project, which recruited 1,450 participants, investigated the potential of wearable devices to measure and predict three chronic conditions: depression, multiple sclerosis (MS) and epilepsy. These conditions affect more than 330m people across the world, and are a major cause of disability.
The scale of RADAR-CNS was unusual. While most digital health projects tend to be small-scale, RADAR-CNS achieved very high recruitment, retention and engagement rates and, according to the researchers, it has set a quality benchmark for future studies in this field.
Researchers assessed seven wearable devices including smartphones, smart watches and activity trackers. The project had three major outcomes:
As well as involving patients, the research team surveyed more than 1,000 healthcare professionals to understand how technology can complement face-to-face treatment and how data can help people to manage their own condition.
Professor Matthew Hotopf, co-lead for the project and vice-dean of research at the Institute of Psychiatry, Psychology and Neuroscience, King’s College London, said that while “huge advances” had been made in the use of technology to track health, until now the “quality and robustness of available data to properly evaluate these has been largely lacking.” He went on: “Over six years, RADAR-CNS has been finding answers to questions about the viability and usefulness of smartphones and wearable tech for managing illness, and the steps that need to be taken to integrate these into clinical practice.”
Hotopf said that the insights provided by patients with the three conditions had been “invaluable”. He had every confidence, he said, that the impact of the work would be “far-reaching and has the potential to improve the lives of thousands of people.”
The use of wearable technology to remotely monitor chronic conditions shows great promise and has already been adopted on a relatively small scale by some hospital trusts. It can hugely improve quality of life for patients by reducing their need for hospital appointments, free up clinician time and improve patient outcomes by identifying problems or anomalies more quickly. Technology should never be a substitute for good clinical care, but it’s encouraging to see such a large-scale study that has put patient voice at the heart of the research. Capturing data at source in an automated way improves the quality of information which can be used directly by patients, health providers, researchers and innovators.